Current Status of Colorectal Cancer
Colorectal cancer (CRC) is one of the most common malignant tumors in China, with approximately 555,000 new cases, accounting for approximately 10% of all malignant tumors. Approximately 30% of colorectal cancer patients have already developed distant metastasis when diagnosed.
The treatment of colorectal cancer is mainly surgical resection, supplemented by chemotherapy and radiotherapy. At present, as the efficacy of chemotherapy has entered a plateau period, molecular targeted therapy has become the main treatment for improving the prognosis of advanced colorectal cancer.
ColoScreen Gene Mutation Detection Panels
Aperbio's ColoScreen panels utilize advanced digital PCR technology to detect key gene mutations in colorectal cancer, enabling precision medicine approaches for patient stratification and treatment selection.
ColoScreen 8 Gene Mutation Detection Kit
SKU: AS-GX-008Comprehensive 8-gene panel for colorectal cancer mutation profiling. This kit detects clinically actionable mutations across key genes involved in colorectal cancer pathogenesis and therapeutic response.
Gene Targets and Clinical Significance
| Gene | Mutation Type | Clinical Significance | Category |
|---|---|---|---|
| KRAS | Exon 2, 3, 4 | Predicts resistance to EGFR inhibitors (Cetuximab, Panitumumab) | Resistance |
| NRAS | Exon 2, 3, 4 | Predicts resistance to EGFR inhibitors | Resistance |
| BRAF | V600E | Poor prognosis indicator; predicts resistance to EGFR inhibitors | Prognostic |
| PIK3CA | Exon 9, 20 | Potential therapeutic target; associated with PI3K pathway activation | Driver |
| TP53 | Multiple hot spots | Tumor suppressor; indicates genomic instability | Driver |
| APC | Truncating mutations | Early event in colorectal carcinogenesis; Wnt pathway activation | Driver |
| SMAD4 | Loss of function | TGF-beta pathway disruption; associated with metastasis | Prognostic |
| FBXW7 | Multiple mutations | Tumor suppressor; regulates protein degradation | Driver |
ColoScreen Extended Mutation Detection Kit
SKU: AS-GX-012Extended panel covering additional clinically relevant genes for comprehensive molecular profiling of colorectal cancer, including genes associated with hereditary CRC syndromes and rare actionable mutations.
Additional Gene Targets
| Gene | Relevance | Clinical Application |
|---|---|---|
| MSH2 | MMR deficiency | Lynch syndrome screening; immunotherapy response prediction |
| MLH1 | MMR deficiency | Lynch syndrome screening; MSI status determination |
| MSH6 | MMR deficiency | Lynch syndrome screening |
| PMS2 | MMR deficiency | Lynch syndrome screening |
| PTEN | Tumor suppressor | PI3K pathway regulation; therapeutic target |
| AKT1 | Oncogene | PI3K/AKT pathway activation |
| EGFR | Receptor tyrosine kinase | Amplification analysis; therapeutic target |
| HER2 | Receptor tyrosine kinase | Anti-HER2 therapy candidate |
Technology Platform
Digital PCR Technology
Ultra-sensitive detection with absolute quantification. Detects mutations at frequencies as low as 0.01% with high precision and reproducibility.
Rapid Turnaround Time
Results available within 2-3 hours from sample to report. Enables rapid clinical decision-making for time-sensitive treatment planning.
Multiplex Detection
Simultaneous detection of multiple mutations in a single reaction. Cost-effective and efficient use of precious clinical samples.
Quantitative Analysis
Absolute quantification of mutant allele frequency. Monitor treatment response and detect emerging resistance mutations.
Liquid Biopsy Compatible
Analyze circulating tumor DNA (ctDNA) from plasma samples. Non-invasive monitoring and minimal residual disease detection.
Clinical Grade
CE-IVD marked and manufactured under ISO 13485 quality management system. Reliable results for clinical decision-making.
Clinical Applications
Treatment Selection
Identify patients likely to respond to anti-EGFR therapy (Cetuximab, Panitumumab) by detecting RAS/RAF wild-type status.
Hereditary Screening
Detect MMR gene mutations associated with Lynch syndrome for cascade screening of family members.
Prognosis Assessment
BRAF V600E and other mutations provide important prognostic information for treatment planning.
Resistance Monitoring
Track emergence of resistance mutations during treatment and guide therapy modification decisions.
Request More Information
Learn more about our ColoScreen panels and how they can support your colorectal cancer diagnostic and treatment decisions.
Contact Us